Casdin Capital leads the $50M extension; funding will support commercial launch of SYNTAX™ the world’s first enzymatic DNA printer. PARIS & SOUTH SAN FRANCISCO, July 29, 2020-- DNA Script today announced a $50 million extension to its Series B financing, bringing the total investment of this round to $89 million. This oversubscribed round is led by Casdin Capital and joined by Danaher Life Sciences, Agilent Technologies, Merck KGaA, Darmstadt, Germany, through its corporate venture arm, M Ventures — three of the world’s leaders in oligo synthesis — LSP, the Bpifrance Large Venture Fund and Illumina Ventures.